Relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine in chronic kidney disease: a secondary analysis of the DANFLU-1 trial

30 August 2024 (08:00 - 17:30)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Katja Vu Bartholdy

Copenhagen University Hospital, Copenhagen (Denmark)

3 More presentations in this session

Presentation thumbnail

State-of-the-art lecture on caring for kidney disease patients in a cardiology setting: what is important?

Professor C. Wanner (Wuerzburg, DE)

Presentation thumbnail

Prognostic value of C-reactive protein / albumin ratio for amputation and/or mortality after lower extremity revascularization in haemodialysis patients with peripheral artery disease

Assistant Professor H. Takahashi (Toyoake, JP)

Abstract Slides Video

Presentation thumbnail

Association of a history of acute kidney injury with major adverse cardiovascular events in chronic kidney disease patients

Doctor B. Tyl (La Garenne Colombes Cedex, FR)

Abstract Slides Video

Access the full session

Session thumbnail

Caring for kidney disease patients in a cardiology setting: what is important?

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

You may be interested in

Congress Presentation

DANFLU-2: High-Dose vs. Standard-Dose Influenza Vaccine and Cardio-Respiratory Outcomes in Older Adults

Congress Presentation

Results from the largest ever individually randomised influenza vaccine effectiveness study

Congress Presentation

Effect of high-dose vs. standard-dose quadrivalent influenza vaccine on death and hospitalizations in older adults with cardiovascular disease: a prespecified analysis of the DANFLU-1 study

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources